Page last updated: 2024-12-08
pf 1022a
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Market Indicators
Description
PF 1022A: structure given in first source; isolated from Mycelia Sterilia [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Cross-References
| ID Source | ID |
|---|---|
| PubMed CID | 159590 |
| CHEMBL ID | 186158 |
| CHEBI ID | 180461 |
| SCHEMBL ID | 14030033 |
| MeSH ID | M0203516 |
Synonyms (23)
| Synonym |
|---|
| CHEBI:180461 |
| pf1022a |
| cyclo(d-2-hydroxypropanoyl-n-methyl-l-leucyl-3-phenyl-d-2-hydroxypropanoyl-n-methyl-l-leucyl-d-2-hydroxypropanoyl-n-methyl-l-leucyl-3-phenyl-d-2-hydroxypropanoyl-n-methyl-l-leucyl) |
| pf 1022 |
| cyclo(d-2-hydroxypropanoyl-n-methyl-l-leucyl-3-phenyl-d-2-hydroxypropanoyl-n-metrhyl-l-leucyl-d-2-hydroxypropanoyl-n-methyl-l-leucyl-3-phenyl-d-2-hydroxypropanoyl-n-methyl-l-leucyl) |
| pf 1022a |
| pf-1022a |
| CHEMBL186158 |
| 133413-70-4 |
| (3s,6r,9s,12r,15s,18r,21s,24r)-6,18-dibenzyl-4,10,12,16,22,24-hexamethyl-3,9,15,21-tetrakis(2-methylpropyl)-1,7,13,19-tetraoxa-4,10,16,22-tetrazacyclotetracosane-2,5,8,11,14,17,20,23-octone |
| ec 444-350-6 |
| cyclo(d-lactyl-l-n-methylleucyl-d-3-phenyllactyl-l-n-methylleucyl-d-lactyl-l-n-methylleucyl-d-3-phenyllactyl-l-n-methylleucyl) |
| (3s,6r,9s,12r,15s,18r,21s,24r)-6,18-dibenzyl-3,9,15,21-tetraisobutyl-4,10,12,16,22,24-hexamethyl-1,7,13,19-tetraoxa-4,10,16,22-tetraazacyclo-tetracosane-2,5,8,11,14,17,20,23-octaone |
| HY-12361 |
| CS-3377 |
| SCHEMBL14030033 |
| AKOS030526415 |
| pf1022 |
| EX-A1669 |
| MS-31776 |
| DTXSID201335234 |
| cyclo[n(me)leu-d-oala-n(me)leu-d-ophe-n(me)leu-d-oala-n(me)leu-d-ophe] |
| GLXC-26269 |
Research Excerpts
Overview
PF 1022A is a member of a new class of cyclic depsipeptides with antiparasitic activity.
| Excerpt | Reference | Relevance |
|---|---|---|
| "PF 1022A is a member of a new class of cyclic depsipeptides with antiparasitic activity. " | ( In vivo activities of the new anthelmintic depsipeptide PF 1022A. Harder, A; Kalbe, J; Mencke, N; Schnieder, T; von Samson-Himmelstjerna, G, 2000) | 2 |
Bioavailability
| Excerpt | Reference | Relevance |
|---|---|---|
| "To enhance the bioavailability of PF1022A (cyclo(D-lactyl-L-N-methylleucyl-D-3-phenyllactyl-L-N-met hylleucyl-D-lactyl-L-N-methylleucyl-D-3-phenyllactyl-L-N- methylleucyl)), a newly developed antinematode drug, we examined whether the new drug has polymorphism or not." | ( Effects of amorphous and polymorphs of PF1022A, a new antinematode drug, on Angiostrongylus costaricensis in mice. Hashimoto, H; Kachi, S; Terada, M, 1998) | 0.3 |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Drug Classes (1)
| Class | Description |
|---|---|
| cyclooctadepsipeptide | A cyclodepsipeptide consisting of eight hydroxy- or amino-acids joined in sequence to give a macrocycle. They form the basis of a relatively new class of anthelmintic agents with a novel mechanism of action. |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
Bioassays (8)
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID203794 | Anthelmintic activity against Haemonchus contortus nematode in sheep was determined as a function of >/= 90% egg reduction after p.o. administration | 1998 | Bioorganic & medicinal chemistry letters, May-05, Volume: 8, Issue:9 | PF1022A--a novel anthelmintic cyclooctadepsipeptide. Modification and exchange of the N-methyl leucine residues. |
| AID251466 | anthelmintic activity as the percent reduction in faecal egg count in sheep infected with 5000 Haemonchus contortus L3 larvae at 0.1 mg/kg | 2004 | Bioorganic & medicinal chemistry letters, Dec-20, Volume: 14, Issue:24 | Chimeric cyclodepsipeptides as mimetics for the anthelmintic PF1022A. |
| AID251000 | anthelmintic activity as the eggs per gram of faeces in sheep infected with 5000 Haemonchus contortus L3 larvae at 0.01 mg/kg | 2004 | Bioorganic & medicinal chemistry letters, Dec-20, Volume: 14, Issue:24 | Chimeric cyclodepsipeptides as mimetics for the anthelmintic PF1022A. |
| AID250998 | anthelmintic activity as the eggs per gram of faeces in sheep infected with 5000 Haemonchus contortus L3 larvae at 0.1 mg/kg | 2004 | Bioorganic & medicinal chemistry letters, Dec-20, Volume: 14, Issue:24 | Chimeric cyclodepsipeptides as mimetics for the anthelmintic PF1022A. |
| AID203793 | Anthelmintic activity against Haemonchus contortus nematode in sheep was determined as a function of >/= 90% egg reduction after i.v. administration | 1998 | Bioorganic & medicinal chemistry letters, May-05, Volume: 8, Issue:9 | PF1022A--a novel anthelmintic cyclooctadepsipeptide. Modification and exchange of the N-methyl leucine residues. |
| AID251467 | anthelmintic activity as the percent reduction in faecal egg count in sheep infected with 5000 Haemonchus contortus L3 larvae at 0.01 mg/kg | 2004 | Bioorganic & medicinal chemistry letters, Dec-20, Volume: 14, Issue:24 | Chimeric cyclodepsipeptides as mimetics for the anthelmintic PF1022A. |
| AID94929 | Percent reduction of Haemonchus contortus in immunosuppressed jird (Meriones unguiculatus) when CDP administered 0.11 mg/jird orally | 2003 | Journal of medicinal chemistry, May-22, Volume: 46, Issue:11 | Restricted conformation analogues of an anthelmintic cyclodepsipeptide. |
| AID23462 | Partition coefficient in n-octanol/ water system at pH= 7.0 | 1998 | Bioorganic & medicinal chemistry letters, May-05, Volume: 8, Issue:9 | PF1022A--a novel anthelmintic cyclooctadepsipeptide. Modification and exchange of the N-methyl leucine residues. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
Research
Studies (33)
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 9 (27.27) | 18.2507 |
| 2000's | 19 (57.58) | 29.6817 |
| 2010's | 5 (15.15) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
Market Indicators
Research Demand Index: 10.83
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (10.83) All Compounds (24.57) |
Study Types
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 1 (3.03%) | 5.53% |
| Reviews | 5 (15.15%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 27 (81.82%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||